CURRICULUM VITAE

1. **Nume**: Dima Simona Olimpia
2. **Data si locul nasterii:**11 Octombrie 1967, Constanta
3. **Cetatenie:** Romana
4. **Studii:**

Institutia	Perioada	Degrees sau diplome obtinute
Universitatea de Medicina si Farmacie Carol Davila, Facultatea de Medicina Generala, Bucuresti	1989–1995	MD degree, Medicina Gnerala
Universitatea "Ovidius" Constanta	1998–2006	PhD in Stiinte Medicale

5. **Scientific degree:**
   Ph.D. degree in 2006 (Numarul de ordine al Ministerului 632/21.03.2007),cu teza numita "Experimental models in the whole pancreas and islet cell transplantation" la Universitatea Ovidius, Constanta, coordonata de Prof. Dr. Vasile Sarbu
   Doctor habilitat in Medicina 2017
6. **Experienta Profesionala:**

Institutia	Perioada	Pozitia	Descriere
Spitalul Clinic Judetean, Constanta	1995-1999	Attending surgeon	Chirurgie Generala
Universitatea "Ovidius" Constanta, Facultatea de Medicina Generala	2003–2006	CP III, MD Chirurgie Generala	Chirurgie Generala
Institutul Clinic Fundeni, Bucuresti	2006-Prezent	MD Chirurgie Generala	Institutul Clinic Fundeni
Institutul Clinic Fundeni, Bucuresti	2009–Prezent	Coordonator de Cercetare si Dezvoltare	Institutul Clinic Fundeni
Institutul Clinic Fundeni, Bucuresti	2013-2015	CSII	Institutul Clinic Fundeni
Institutul Clinic Fundeni, Bucuresti	2015- Prezent	CSI	Institutul Clinic Fundeni
Institutul Clinic Fundeni, Bucuresti	2017- Prezent	Presedintele Consiliului Stiintific	Institutul Clinic Fundeni

7. **Titlul pozitiei:** Cercetator Stintific I,Coordonator de Cercetare si Dezvoltare a Centrului de Boli Digestive si Transplant de ficat.
   MD, PhD Chirurgie Generala, Institutul Clinic Fundeni
8. **Limbi straine:** Engleza

9. **Competente, Onoruri**
   2007-2014: Secretar al Comisiei 3, Viata si Sanatate, al Colegiului Consultativ, al MCT (Monisterul Educatiei, Cercetarii si Tineretului)-Ordinul Ministerului Educatiei, Cercetarii si Tineretului nr. 965 din 4.05.2007
   Consiliul Consultativ al MCT: 2012-2015
   2012- prezent: Coordonator Stiintific al proiectului: POS CCE Priority Axis 2: Competitivitate prin cercetare, dezvoltare tehnologică și inovare, Operatiunea: 2.2.1. Dezvoltarea infrastucturii C-D existente si crearea de noi infrastructuri C-D (laboratoare, centre de cercetare) 951 / cod SMIS-CSNR 14056, contract de finantare nr. 434 / 21.12.2012 – Centrul de Excelenta in Medicina Translationala (CEMT).
   Membru: Academia Romana de Stiinte Medicale (2017)
10. **Alte Specializari si Calificari:**
    2002-Specializare in Transplantul de insule pancreatice- Curs si cercetare de baza in izolare, purificare si crioconservare a insulelor pancreatice
    2002-2003: Instruire in transplantul si chirurgia ficatului la Institutul Clinic Fundeni.
    2003-Instruire in izolarea insulelor pancreatice, in cadrul Centrului de Transplant si Izolare a Celulelor, Departamentul de Chirurgie, Spitalul Universitatii din Geneva, Elvetia.

2004-Visiting research fellow in transplantul clinic al insulelor pancreatice la Islet Cell Resource Center (SC-ICR) in California de Sud, Departamentul de Diabet, Endocrinologie si Metabolism, Centrul de Cercetare Leslie si Susan Gonda de Genetica si Diabet, California, SUA .

2006–2007-Curs de Instruire in Transplantul de Organe a Societatii Europene de Transplant de Organe. Sesiunea I- Lion, Franta, Sesiunea II, Malmo, Suedia.

Iunie 2007- Sept 2007 Curs de specializare in transplantul de pancreas- Institutul de Diabet pentru Imunologie si Transplant, Universitatea Minnesota, SUA

2009-curs de instruire pentru Diploma Europeana in Divizia de Chirurgie de Transplant a Uniunii Europene a Specialistilor Medicali "Union of European Médecins Spécialistes (UEMS)" si a consiliului European de Chirurgie, Universitatea Semmelweis, Ungaria.

11. Suport in cercetare pe programme/proiecte nationale/ international (Selectie):

Program/Proiect	**Pozitie**	**Perioada**	**Buget (Ron)**
PNCD II P024 "Comparative study of the molecular mechanisms of chronic pancreatitis and pancreatic ductal adenocarcinoma", (MOLPANC). **Publicatii:** An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients with Ductal Pancreatic Adenocarcinoma. **Dima S.** et al. ***Pancreas*. 2012 Oct;41(7):**1001-7. **IF:3.008** Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Cucu D, **Dima S,** et al. ***Pancreas***. 2014 Jul;43(5):795-800. **IF:3.008**	Director de proiect	2007-2010	2.000.000
Pr. no. 4 SEE: "Hepatocellular carcinoma stratification based on noninvasive markers" (***HEPMARK);***	Responsabil stiintific	2014-2017	4.945.612
PCCA-90: „Role of S100A4 and MAP4K4 in pancreatic ductal adenocarcinoma progression" PNII-PT-PCCA 90/2012	Responsabil stiintific	2012-2015	3.000.000
CEEX, Module I P62 "Genic profiles induced by transcriptional suppression of Ets-1 in pancreatic cancer"; (PACAGENTER). **Publicatie:** Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. Lefter LP, **Dima S,** et al. ***Cancer Gene Ther***. 2009, 16(2):137-48. IF:3.887, Times cited:12	Responsabil stiintific	2006-2008	1.500.000
CEEX, Module I P64 "Caveolins 1, 2 and 3 expression in pancreatic cancers, molecular targets in diagnosis and therapy", (CAVEEX). **Publicatii:** Chapter 11: Chronic Pancreatitis as an Inductor of Pancreatic Ca Correlations With Inflammatory Pathway, **Dima SO**, et al. **Book** Acute and Chronic Pancreatitis. ***InTech***, 2015. Pancreatic metastases originating from uterine leiomyosarcoma: a case **Dima SO**, et al. ***World J. Surg. Oncol.*** 2014; 12: 405. IF: 1.408. Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Cucu D, **Dima SO**, et al. ***Pancreas***, 43: 795-800, 2014. IF: 3.008	Responsabil stiintific	2006-2008	1.500.000
CEEX 56/2005 „Gene Expression Profile And Biomarkers Study Correlated With Clinic-pathological Parameters In Pancreatic Cancer "(GENOPACT)	Membru de proiect	2005-2008	15.000.000
Pr. no. 211 SMIS CSNR 692-12650; Gene profile of the non-small cell bronchopulmonary cancer with mediastinal lymph node invasion (GPN2)	Coordonator Stiintific	2010-2014	6.000.000

Project no. 951, SMIS-CSNR code 14056, **"Center Of Excellence In Translational Medicine".**	Responsabil de proiect	2012-2015	43.652.966
Cod proiect: PN-III-P3-3.1-PM-RO-CN-2018-0209, Numar contract:1 BM/2018, **"Prospective validation of angiogenic and inflammatory biomarkers of liver cancer recurrence after surgery"**	Membru de echipa	2017-2020	Total budget for Fundeni Clinical Institute: 41.280
Cod proiect: PN-III-P4-ID-PCCF2016-0158, Numar contract: PCCF 17/2018, „Mechanisms and biomarkers of response and resistance to current targeted therapies in gastric cancer" (http://icfundeni.ro/therres/)	Membru de echipa	2018-2022	3.400.000

12. Alte mentiuni:

In ultima decada, mi-am concentrat studiile pe cercetarea oncogenica a cancerului de panceas, colangiocarcinomului si a carcinomului hepatocelular si am fost implicata in studii clinice corelate. Am facut parte dintr-o echipa de cercetatori de la Centrul National de Cancer Singapore, Duke-NUS Graduate Medical School Singapore, Institutul Clinic Fundeni si Universitatea Koen Kaen, care au facut progrese majore in descoperirea bazelor moleculare a colangiocarcinomului (*Nat. Genetics (2013) 45 (12): 1474-8, 1470-3).* Am fost membru al unei echipe a proiectului numit "Gene Expression Profile and Biomarkers Study correlated with Clinic and pathological parameters in Pancreatic Cancer" (acronym: CEEX 56). Acesta este una dintre cele mai mari This is one of the largest available PDAC dataset (GSE1547) …… Rezultatele acestui studiu au fost publicate in articolul cu titlul. "Combined Gene Expression Analysis of Whole-Tissue and Microdissected Pancreatic Ductal Adenocarcinoma identify Genes Specifically Overexpressed in Tumor Epithelia" din 2008,publicat in Hepatogastroenterology Journal. Acest articol a fost citat in jurnale cu un factor de impact crescut precum *Nature Medicine (2011), Nature (2013)* sau *Cell (2012)*. Descoperiri recente au aratat ca PDAC este o boala ce poate fi impartita in doua subtipuri moleculare.. Dataset din studiile noastre asupra probelor de tumori PDAC au fost incluse in analiza combinata a profilelor transcriptionale conduse de Collisson si colab. si publicat in Nat Med in 2011, ceea ce a dus la definirea a 3 subtipuri de cancer pancreatic: clasic, quasi-mezenchimal si exocrin-like. In plus, ca membru al unei echipe de cercetatori implicati in poiectul "The role of S100A4 and MAP4K4 in the progression of pancreatic ductal adenocarcinoma" (acronym: S100MAP) am contribuit la patentarea (filed with OSIM NO A / 00927) "The precise methods to establish a personalized chemogram for pancreatic cancer treatment". Inventia va permite stabilirea unui sistem de co-cultura 3-D utilizand celulele PDAC in co-cultura cu celule stromale (PSC) pe sisteme polimerice care mimeaza matricea extracelulara, care este parte din micromediul PDAC. Unul dintre cele mai mari proiecte ale echipei noastre in care sunt implicata in pozitia de coordinator stiintific este CEMT, "Centrul de Excelenta in Medicina Translationala"; finantare: POS CCE. Scopurile CEMT sunt sa realizeze studii translationale cu aplicatii clinice pe pacienti cu boli hepato-bilio-pancreatice.

Colaborari internationale in cercetare cu:

- National Cancer Centre Singapore
- Massachusetts General Hospital Cancer Center, Harvard School of Medicine, Boston
- Johns Hopkins University School of Medicine
- Pasteur Institute - Brancusi bilateral project: Romania- France- The National Authority for Scientific Research and ACIP A24 project- Sponsor – Institut Pasteur.
- The Sheba Regenerative Medicine, Stem Cell and Tissue Engineering Center
- Department of Molecular Pathology, Tohoku University School of Medicine, Tokyo, Japan

Pana in prezent,eforturile mele in cercetare au rezultat in 100+ publicatii (Hirsch index-15, Citation number: 1235) (http://www.researcherid.com/rid/B-8822-2017). In plus, sunt autor/co-autor in 6 capitole din carti nationale si in 3 capitole din carti internationale.



Publicatii relevante (selectie):

1) Badea L, Herlea V, **Dima S**, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. *Hepatogastroenterology* 55: 2016-2027, 2008. *IF*: 0.904. ***Times Cited: 190***

2) Lefter LP, **Dima S**, Sunamura M, Furukawa T, Sato Y, Abe M, Chivu M, Popescu I, Horii A. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. *Cancer Gene Ther* 16: 137-148, 2009. *IF*: 3.887. ***Times Cited: 16.***

3) Chivu EM, Necula LG, Dragu D, Badea L, **Dima S**, Tudor S, Nastase A, Popescu I, Diaconu CC. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. *Hepato-gastroenterology* 57: 1453-1464, 2010. *IF*::0.667 ***Times Cited: 23.***

4) **Dima S**, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. *Pancreas* 41: 1001-7, 2012. *IF*: 2.607. ***Times Cited: 30***

5) Popescu, I.; Dima, S. O. Domino liver transplantation: How far can we push the paradigm?Liver Transplantation 18 (1): 22-28, 2012. ***Times Cited: 32***

6) Yamanaka S, Olaru AV, An F, Luvsanjav D, Jin Z, Agarwal R, Tomuleasa C, Popescu I, Alexandrescu S, **Dima S**, Chivu-Economescu M, Montgomery EA, Torbenson M, Meltzer SJ, Selaru FM. MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. *Dig Liver Dis* 44: 589-596, 2012. *Impact Factor* 2012:3.054; ***Times Cited: 35.***

7) Chan-On W, Nairismagi ML, Ong CK, Lim WK, **Dima S**, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nat Genet* 45: 1474-1478, 2013. *IF*: 35.209; ***Times Cited: 169.***

8) Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, **Dima S**, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat Genet* 45: 1470-1473, 2013. *IF*: 35.209; ***Times Cited: 249.***

9) Dumitrascu T*, **Dima S*,** Brasoveanu V, Stroescu C, Herlea V, Moldovan S, Ionescu M, Popescu I. Impact of a portal/superior mesenteric vein resection during pancreatico-duodenectomy for pancreatic head adenocarcinoma. Minerva Chir 2014; 69: 301-313, (*)co-first authors. IF: 0,678. ***Times Cited: 5.***

10) Dumitrascu T, **Dima S,** Stroescu C, Scarlat A, Ionescu M, Popescu I. Clinical value of spleen-preserving distal pancreatectomy: a case-matched analysis with a special emphasis on the postoperative systemic inflammatory response. J Hepatobiliary Pancreat Sci 2014; 21: 654-662, (*) co-first authors. IF:2,994. **Times Cited: 4 .**

11) Ionescu-Tirgoviste C, Gagniuc PA, Gubceac E, Mardare L, Popescu I, **Dima S**, Militaru M. A 3D map of the islet routes throughout the healthy human pancreas Sci Rep. 2015 29;5:14634., IF: 5.578, **Times Cited: 19.**

12) Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Peng H, Ishida M, Li L, Saito A, Kamiya A, Hamilton JP, Fu R, Olaru AV, An F, Popescu I, Iacob R, **Dima S,** Alexandrescu ST, Grigorie R, Nastase A, Berindan-Neagoe I, Tomuleasa C, Graur F, Zaharia F, Torbenson MS, Mezey E, Lu M, Selaru FM. Oncotarget. 2015; 6(8):5666-77. IF:6.627, **Times Cited: 26**.

13) Chng KR, Chan SH, Ng AH,Li C, Jusakul A, Bertrand D, Wilm A, Choo SP, Tan DM, Lim KH, Soetinko R, Ong CK, Duda DG, **Dima S,** Popescu I, Wongkham C, Feng Z, Yeoh KG, Teh BT,Yongvanit P, Wongkham S, Bhudhisawasdi V, Khuntikeo N, Tan P, Pairojkul C, Ngeow J, Nagarajan N. Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma.EBioMedicine. 2016 Jun; 8:195-202., IF:1.37, **Times Cited: 15.**

14) Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung AYF, Ooi LLPJ, Lim KH, **Dima S**, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discov*, 2017. pii: CD-17-0368. *IF:* 20.011

15) Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, JengKS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, **Dima S**, PopescuI, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors *Sci Rep*. 2017 Mar 9; 7:44123; IF: 5.228. ***Times Cited:9.***

16) Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, **Dima S**, Duda DG, Teh BT, Popescu I, Lim TK. Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. *Am J Cancer Res.* 2017; 1;7(3):484-502. eCollection 2017. IF: 3.425.

17) Hong TS, Grassberger C, Yeap B, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, **Dima S,** Eyle C, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma hepatocyte growth factor as a potential biomarker for susceptibility to radiation-induced liver dysfunction in liver cancer patients treated with radiotherapy. *Nature Precision Oncology* 2018; doi: 10.1038/s41698-018-0065-y.

18) Prognostic Factors in Patients with Surgical Resection of Pancreatic Neuroendocrine Tumours. **Dima SO,** Dumitrascu T, Pechianu C, Grigorie RT, Brasoveanu V, Sorop A, Lupescu I,Purnichescu-Purtan R, Croitoru A, Bacalbasa N, Tanase A, Tomescu DR, Herlea V , Popescu I. *Acta Endo* (Buc) 2018 14: 389-393